2256 — Abbisko Cayman Share Price
0.000.00%
Last trade - 00:00- HK$2.04bn
- -HK$58.97m
- CNY19.06m
- 26
- 13
- 66
- 22
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.95 | ||
| Price to Tang. Book | 0.95 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 98.75 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -21.4% | ||
| Return on Equity | -19.95% | ||
| Operating Margin | -2252.95% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | n/a | 22.68 | n/a | 19.06 | 349.76 | 278.71 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Abbisko Cayman Ltd is a China-based clinical-stage biopharmaceutical company. The Company is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The Company owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Company’s products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).
Directors
- Yao-Chang Xu CHM (64)
- Zhui Chen CFD (47)
- Hongping Yu CFD (53)
- Richard Yeh CFO (53)
- Zhen Zhang VPR (48)
- Yongyi Li GCN (46)
- Jing Ji OTH (51)
- Kewei Xie OTH (60)
- Yanmin Tang NED (49)
- Gavin Guoyao Xia NED (42)
- Hongbin Sun NID (46)
- Piaoyang Sun NID (63)
- Lei Wang NID (49)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 28th, 2018
- Public Since
- October 13th, 2021
- No. of Employees
- 252
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 702,199,350
- Address
- Building 3, No. 898, SHANGHAI, 200120
- Web
- https://www.abbisko.com/
- Phone
- +86 2168912098
- Auditors
- Ernst & Young CPA
Upcoming Events for 2256
Abbisko Cayman Ltd Annual Shareholders Meeting
Half Year 2024 Abbisko Cayman Ltd Earnings Release
Similar to 2256
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
Beigene
Stock Exchange of Hong Kong Limited
FAQ
What is the Abbisko Cayman share price?
As of Today at 19:00 UTC, shares in Abbisko Cayman are trading at HK$2.90. This share price information is delayed by 15 minutes.
How has the Abbisko Cayman share price performed this year?
Shares in Abbisko Cayman last closed at HK$2.90 and the price had moved by -0.34% over the past 365 days. In terms of relative price strength the Abbisko Cayman share price has outperformed the FTSE Developed Asia Pacific Index by +4.02% over the past year.
What are the analyst and broker recommendations for Abbisko Cayman?
The overall consensus recommendation for Abbisko Cayman is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Abbisko Cayman dividend yield?
Abbisko Cayman does not currently pay a dividend.
Does Abbisko Cayman pay a dividend?
Abbisko Cayman does not currently pay a dividend.
When does Abbisko Cayman next pay dividends?
Abbisko Cayman does not currently pay a dividend.
How do I buy Abbisko Cayman shares?
To buy shares in Abbisko Cayman you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Abbisko Cayman?
As of the previous close price of HK$2.90, shares in Abbisko Cayman had a market capitalisation of HK$2.04bn.
Where are Abbisko Cayman shares listed?
Here are the trading details for Abbisko Cayman:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2256
What kind of share is Abbisko Cayman?
Based on an overall assessment of its quality, value and momentum Abbisko Cayman is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Abbisko Cayman share price forecast for 2024?
The analyst consensus target price for shares in Abbisko Cayman is HK$8.78. That is 202.64% above the last closing price of HK$2.90.
Analysts covering Abbisko Cayman currently have a consensus Earnings Per Share (EPS) forecast of -CNY0.31 for the next financial year.
What is the trend in the Abbisko Cayman share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abbisko Cayman. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -0.04%.
As of the last closing price of HK$2.90, shares in Abbisko Cayman were trading +1.13% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Abbisko Cayman PE Ratio?
The Abbisko Cayman PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$2.90.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Abbisko Cayman?
Abbisko Cayman's management team is headed by:
- Yao-Chang Xu - CHM
- Zhui Chen - CFD
- Hongping Yu - CFD
- Richard Yeh - CFO
- Zhen Zhang - VPR
- Yongyi Li - GCN
- Jing Ji - OTH
- Kewei Xie - OTH
- Yanmin Tang - NED
- Gavin Guoyao Xia - NED
- Hongbin Sun - NID
- Piaoyang Sun - NID
- Lei Wang - NID